Abstract
Tyrosine kinase receptors are expressed on the surface of tumor and/or endothelial cells and represent attractive targets for new anti-cancer treatment strategies. The so-called “small molecule” tyrosine kinase inhibitors have been designed to interact with the intracellular ATP binding site of these receptors, subsequently causing arrest of tumor cell proliferation, as well as induction of apoptosis and tumor migration. Furthermore, these molecules can impact on tumor angiogenesis. Tyrosine kinase inhibitors have been evaluated in several clinical trials for various adult malignant tumor entities and are currently being studied in pediatric solid malignancies. In this review, we will address the data available supporting the potential use of tyrosine kinase inhibitors in solid malignancies of childhood.
Keywords: Tyrosine kinase, tyrosine kinase inhibitors, imatinib, gefitinib, erlotinib, embryonic tumors, sarcomas, pediatric oncology
Current Cancer Drug Targets
Title: Small Molecule Tyrosine Kinase Inhibitors: Potential Role in Pediatric Malignant Solid Tumors
Volume: 8 Issue: 1
Author(s): Jochen Rossler, Birgit Geoerger, Melissa Taylor and Gilles Vassal
Affiliation:
Keywords: Tyrosine kinase, tyrosine kinase inhibitors, imatinib, gefitinib, erlotinib, embryonic tumors, sarcomas, pediatric oncology
Abstract: Tyrosine kinase receptors are expressed on the surface of tumor and/or endothelial cells and represent attractive targets for new anti-cancer treatment strategies. The so-called “small molecule” tyrosine kinase inhibitors have been designed to interact with the intracellular ATP binding site of these receptors, subsequently causing arrest of tumor cell proliferation, as well as induction of apoptosis and tumor migration. Furthermore, these molecules can impact on tumor angiogenesis. Tyrosine kinase inhibitors have been evaluated in several clinical trials for various adult malignant tumor entities and are currently being studied in pediatric solid malignancies. In this review, we will address the data available supporting the potential use of tyrosine kinase inhibitors in solid malignancies of childhood.
Export Options
About this article
Cite this article as:
Rossler Jochen, Geoerger Birgit, Taylor Melissa and Vassal Gilles, Small Molecule Tyrosine Kinase Inhibitors: Potential Role in Pediatric Malignant Solid Tumors, Current Cancer Drug Targets 2008; 8 (1) . https://dx.doi.org/10.2174/156800908783497113
DOI https://dx.doi.org/10.2174/156800908783497113 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Targets for Apoptosis Modulation: BAG3 Protein and Other Co- Chaperones
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Single-Cell Sequencing for Drug Discovery and Drug Development
Current Topics in Medicinal Chemistry Promising Activity of Mammalian Target of Rapamycin Inhibitors in Hematologic Malignancies Therapy
Current Signal Transduction Therapy Applying Epigenetics to Alzheimer’s Disease via the Latent Early–life Associated Regulation (LEARn) Model
Current Alzheimer Research Development of personalized molecular therapy for acute myeloid leukemia
Current Pharmaceutical Biotechnology The Structure and Functions of P-Glycoprotein
Current Medicinal Chemistry Hypothalamic mTOR: The Rookie Energy Sensor
Current Molecular Medicine Therapeutic Management of Atopic Eczema
Current Drug Metabolism A Possible Approach for Stem Cell Gene Therapy of Fanconi Anemia
Current Gene Therapy Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities
Current Medicinal Chemistry Microbes, Immunity and Multiple Sclerosis: An Update
Current Immunology Reviews (Discontinued) Red Blood Cell-Encapsulated L-Asparaginase: Potential Therapy of Patients with Asparagine Synthetase Deficient Acute Myeloid Leukemia
Protein & Peptide Letters Design of New Drug Molecules to be Used in Reversing Multidrug Resistance in Cancer Cells
Current Cancer Drug Targets Personalized Therapies in Pediatric Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design Thiourea and Guanidine Derivatives as Antimalarial and Antimicrobial Agents<sup>§</sup>
Current Topics in Medicinal Chemistry Heavy Metal Toxicity in Humans and its Preventive and Control Measures
Current Nutrition & Food Science Potential Pathways for CNS Drug Delivery Across the Blood-Cerebrospinal Fluid Barrier
Current Pharmaceutical Design Regulation of the Immune Response by Natural IgM: Lessons from Warm Autoimmune Hemolytic Anemia
Current Pharmaceutical Design Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment
Current Pharmaceutical Design